Poster Viewing Session II - Clinical
Young Investigators present their poster in a short movie and reply live to questions moderated by the session chairs.
Now Playing: Poster Viewing Session II - Clinical
Poster Viewing Session II - Clinical
Moderators: Gilels Edan & Edgardo Cristiano
- Peripheral neuropathy as potential side effect of teriflunomide: Serena Borrelli (Brussels, Belgium)
- Sodium/potassium ratio as a conversion predictor from CIS to MS: Marlene Arbeu-Reyes (Mineral de la Reforma, Mexico)
- Quantify upper limb impairment in the ADL in people with Multiple Sclerosis: Marco Pisa (Milan, Italy)
- CONFIDENCE: Real-world effectiveness of ocrelizumab in relapsing MS over 18 months: Julius Eggebrecht (Grenzach-Wyhlen, Germany)
- Exercise therapy as supplemental treatment in early multiple sclerosis: a RCT: Morten Riemenschneider (Aarhus, Denmark)
- Humoral immune response to SARS-CoV2 vaccines in multiple sclerosis and controls: Gabriel Bsteh (Vienna, Austria)
- Prevalence of PTSD in Russian population of MS patients: Ivan Kalinin (Saint-Petersburg, Russia)
- Quality of life and fear of disease progression in MS patients with PTSD: Mariia Andreeva (Saint-Petersburg, Russia)
- Frequency of New Silent MRI lesions in MOGAD and AQP4-NMOSD: Valentina Camera (Oxford, United Kingdom)
- The impact of COVID-19 on patients with neuromyelitis optica beyond infection risk: Hexiang Yin (Beijing, China)
- Long-term disability outcomes in multiple sclerosis: a 25-year follow-up study: Sena Destan Bunul (Kocaeli, Turkey)